Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 2
2004 2
2007 1
2010 1
2012 1
2013 1
2014 1
2015 2
2016 1
2020 2
2021 1
2024 2
2025 2
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Stealth Nanocarriers in Cancer Therapy: a Comprehensive Review of Design, Functionality, and Clinical Applications.
Saadh MJ, Mustafa MA, Kumar A, Alamir HTA, Kumar A, Khudair SA, Faisal A, Alubiady MHS, Jalal SS, Shafik SS, Ahmad I, Khry FAF, Abosaoda MK. Saadh MJ, et al. AAPS PharmSciTech. 2024 Jun 18;25(6):140. doi: 10.1208/s12249-024-02843-5. AAPS PharmSciTech. 2024. PMID: 38890191 Review.
The in vivo behavior of stealth nanocarriers and their impact on pharmacokinetics, biodistribution, and toxicity were also systematically examined. Additionally, the review presented clinical applications, case studies of approved nanocarrier-based can …
The in vivo behavior of stealth nanocarriers and their impact on pharmacokinetics, biodistribution, and toxicity were also sys …
A Systematic Review of Advanced Drug Delivery Systems: Engineering Strategies, Barrier Penetration, and Clinical Progress (2016-April 2025).
Uzakova AB, Yergaliyeva EM, Yerlanuly A, Mukatayeva ZS. Uzakova AB, et al. Pharmaceutics. 2025 Dec 22;18(1):11. doi: 10.3390/pharmaceutics18010011. Pharmaceutics. 2025. PMID: 41599119 Free PMC article. Review.
Included studies focused on experimental or clinical data for nanocarrier platforms (liposomes, lipid nanoparticles, polymer systems, biomimetic carriers, extracellular vesicles). ...Liposomes and lipid nanoparticles (LNPs) remain the most clinically v …
Included studies focused on experimental or clinical data for nanocarrier platforms (liposomes, lipid nanoparticles, polymer s …
The Targeted-liposome Delivery System of Antitumor Drugs.
Wu WD, Yi XL, Jiang LX, Li YZ, Gao J, Zeng Y, Yi RD, Dai LP, Li W, Ci XY, Si DY, Liu CX. Wu WD, et al. Curr Drug Metab. 2015;16(10):894-910. doi: 10.2174/138920021610151210184654. Curr Drug Metab. 2015. PMID: 26652257 Review.
Here, the author reviewed the important targets for cancer therapy and the pharmacokinetic behavior of liposomal drugs in vivo, as well as the application of the targeting liposomal system in cancer therapy. Considering further application for clinical …
Here, the author reviewed the important targets for cancer therapy and the pharmacokinetic behavior of liposomal drugs in vivo …
Cell membrane coated nanocarriers - an efficient biomimetic platform for targeted therapy.
Dash P, Piras AM, Dash M. Dash P, et al. J Control Release. 2020 Nov 10;327:546-570. doi: 10.1016/j.jconrel.2020.09.012. Epub 2020 Sep 8. J Control Release. 2020. PMID: 32911013 Review.
Traditional methods of delivering drugs and therapeutics faced issues of solubility, sustained release, not enough amount getting through the diseased site, for e.g a tumor. Various formulations of liposomes, polymers, dendrimers, etc have succeeded and made their way for …
Traditional methods of delivering drugs and therapeutics faced issues of solubility, sustained release, not enough amount getting through th …
Development of Promitil , a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside.
Gabizon A, Shmeeda H, Tahover E, Kornev G, Patil Y, Amitay Y, Ohana P, Sapir E, Zalipsky S. Gabizon A, et al. Adv Drug Deliv Rev. 2020;154-155:13-26. doi: 10.1016/j.addr.2020.07.027. Epub 2020 Aug 7. Adv Drug Deliv Rev. 2020. PMID: 32777239 Review.
The pharmacokinetics of MLP was typically stealth with long T (~1 day), slow clearance and small volume of distribution. Interestingly, a longer T , and slower clearance were both correlated with disease stabilization and longer survival. This association of pha …
The pharmacokinetics of MLP was typically stealth with long T (~1 day), slow clearance and small volume of distribution. Inte …
The influence of protein corona on liposomal delivery systems: A comprehensive review.
Mojarad-Jabali S, Fatahi Y, Dinarvand R. Mojarad-Jabali S, et al. Eur J Pharm Sci. 2025 Sep 1;212:107166. doi: 10.1016/j.ejps.2025.107166. Epub 2025 Jun 11. Eur J Pharm Sci. 2025. PMID: 40513682 Free article. Review.
Despite the development of stealth liposomes, completely preventing protein corona formation remains a challenge. ...Recent studies, however, suggest that the protein corona may also be utilized to enhance liposome functionality and targeting. This review …
Despite the development of stealth liposomes, completely preventing protein corona formation remains a challenge. ...Recent st …
Exploring the possible targeting strategies of liposomes against methicillin-resistant Staphylococcus aureus (MRSA).
Mat Rani NNI, Mustafa Hussein Z, Mustapa F, Azhari H, Sekar M, Chen XY, Mohd Amin MCI. Mat Rani NNI, et al. Eur J Pharm Biopharm. 2021 Aug;165:84-105. doi: 10.1016/j.ejpb.2021.04.021. Epub 2021 May 8. Eur J Pharm Biopharm. 2021. PMID: 33974973 Review.
The surface of the liposomes can also be designed and enhanced with drug-release properties, active targeting, and stealth effects to prevent recognition by the mononuclear phagocyte system, thus enhancing its circulation time. The present review aimed to hig …
The surface of the liposomes can also be designed and enhanced with drug-release properties, active targeting, and stealth eff …
From conventional to stealth liposomes: a new Frontier in cancer chemotherapy.
Cattel L, Ceruti M, Dosio F. Cattel L, et al. J Chemother. 2004 Nov;16 Suppl 4:94-7. doi: 10.1179/joc.2004.16.Supplement-1.94. J Chemother. 2004. PMID: 15688621 Review.
The first-generation liposomes (conventional liposomes) comprised a liposome-containing amphotericin B, Ambisome, and Myocet, doxorubicin-containing liposome used in clinical trials to treat metastatic breast cancer. The last generation lipos …
The first-generation liposomes (conventional liposomes) comprised a liposome-containing amphotericin B, Ambisome, and M …
Advantages of liposomal delivery systems for anthracyclines.
Allen TM, Martin FJ. Allen TM, et al. Semin Oncol. 2004 Dec;31(6 Suppl 13):5-15. doi: 10.1053/j.seminoncol.2004.08.001. Semin Oncol. 2004. PMID: 15717735 Review.
Numerous strategies that seek to either exploit or avoid this phenomenon have been used. As a result, several liposomal chemotherapeutic agents are now available in the clinic. STEALTH, a novel liposomal system coated with polyethylene glycol, avoids u …
Numerous strategies that seek to either exploit or avoid this phenomenon have been used. As a result, several liposomal chemotherapeu …
Current status, challenges and prospects of antifouling materials for oncology applications.
Zhang Y, Sun C. Zhang Y, et al. Front Oncol. 2024 May 8;14:1391293. doi: 10.3389/fonc.2024.1391293. eCollection 2024. Front Oncol. 2024. PMID: 38779096 Free PMC article. Review.
Conventional drug delivery systems encountered challenges related to solubility, prolonged release, and inadequate drug penetration at the target region, such as a tumor. Several formulations, such as liposomes, polymers, and dendrimers, have been successful in advancing t …
Conventional drug delivery systems encountered challenges related to solubility, prolonged release, and inadequate drug penetration at the t …
21 results